{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:39:48Z","timestamp":1777959588895,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11739-017-1719-4","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T03:00:15Z","timestamp":1501902015000},"page":"915-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["New anabolic therapies for osteoporosis"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-0439","authenticated-orcid":false,"given":"Salvatore","family":"Minisola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Occhiuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"key":"1719_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrendo.2014.214","volume":"11","author":"SE Papapoulos","year":"2015","unstructured":"Papapoulos SE (2015) Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat Rev Endocrinol 11:69\u201370. doi:\n                        10.1038\/nrendo.2014.214","journal-title":"Nat Rev Endocrinol"},{"key":"1719_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11657-010-0035-7","volume":"5","author":"N Freemantle","year":"2010","unstructured":"Freemantle N, Cooper C, Roux C et al (2010) Baseline observations from the POSSIBLE EU\u00ae study: characteristics of postmenopausal women receiving bone loss medications. Arch Osteoporos 5:61\u201372. doi:\n                        10.1007\/s11657-010-0035-7","journal-title":"Arch Osteoporos"},{"key":"1719_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00198-015-3322-8","volume":"27","author":"KL Holloway","year":"2016","unstructured":"Holloway KL, Henry MJ, Brennan-Olsen SL et al (2016) Non-hip and non-vertebral fractures: the neglected fracture sites. Osteoporos Int 27:905\u2013913. doi:\n                        10.1007\/s00198-015-3322-8","journal-title":"Osteoporos Int"},{"issue":"1\u20132","key":"1719_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1\u20132):136. doi:\n                        10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"key":"1719_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00198-004-1633-2","volume":"15","author":"E Romagnoli","year":"2004","unstructured":"Romagnoli E, Carnevale V, Nofroni I et al (2004) Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical fractures. Osteoporos Int 15:975\u2013980. doi:\n                        10.1007\/s00198-004-1633-2","journal-title":"Osteoporos Int"},{"key":"1719_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/BF03327374","volume":"15","author":"E Romagnoli","year":"2003","unstructured":"Romagnoli E, Carnevale V, Calandra P et al (2003) Impact of fractures on health care in a major university hospital in Rome. Aging Clin Exp Res 15:505\u2013511. doi:\n                        10.1007\/BF03327374","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"1719_CR7","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28(7):2023\u20132034. doi:\n                        10.1007\/s00198-017-4009-0","journal-title":"Osteoporos Int"},{"issue":"7231","key":"1719_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/bmj.320.7231.341","volume":"320","author":"G Salked","year":"2000","unstructured":"Salked G, Cameron ID, Cumming RG et al (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. Br Med J 320(7231):341\u2013346","journal-title":"Br Med J"},{"key":"1719_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1359\/JBMR.040507","volume":"19","author":"M Pfeifer","year":"2004","unstructured":"Pfeifer M, Sinaki M, Geusens P et al (2004) Musculoskeletal rehabilitation in osteoporosis: a review. J Bone Miner Res 19:1208\u20131214. doi:\n                        10.1359\/JBMR.040507","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1719_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1210\/jc.2006-1404","volume":"92","author":"S Boonen","year":"2007","unstructured":"Boonen S, Lips P, Bouillon R et al (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92(4):1415\u20131423. doi:\n                        10.1210\/jc.2006-1404","journal-title":"J Clin Endocrinol Metab"},{"key":"1719_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-13-0435","volume":"169","author":"E Romagnoli","year":"2013","unstructured":"Romagnoli E, Pepe J, Piemonte S et al (2013) Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur J Endocrinol 169:59\u201369. doi:\n                        10.1530\/EJE-13-0435","journal-title":"Eur J Endocrinol"},{"key":"1719_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/841248","author":"C Cipriani","year":"2014","unstructured":"Cipriani C, Pepe J, Piemonte S et al (2014) Vitamin D and its relationship with obesity and muscle. Int J Endocrinol. doi:\n                        10.1155\/2014\/841248","journal-title":"Int J Endocrinol"},{"issue":"6","key":"1719_CR13","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, Drake MT, Mullan RJ et al (2012) Comparative Effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871\u20131880. doi:\n                        10.1210\/jc.2011-3060","journal-title":"J Clin Endocrinol Metab"},{"key":"1719_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1359\/JBMR.041114","volume":"20","author":"BL Riggs","year":"2005","unstructured":"Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177\u2013184. doi:\n                        10.1359\/JBMR.041114","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1719_CR15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1517\/14712598.2014.920815","volume":"14","author":"S Minisola","year":"2014","unstructured":"Minisola S (2014) Romosozumab: from basic to clinical aspects. Expert Opin Biol Ther 14(9):1225\u20131228. doi:\n                        10.1517\/14712598.2014.920815","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"1719_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344(19):1434\u20131441. doi:\n                        10.1056\/NEJM200105103441904","journal-title":"N Eng J Med"},{"key":"1719_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/jbmr.2804","volume":"31","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR et al (2016) A longitudinal study of skeletal histomorphometry at 6 and 24\u00a0months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial. J Bone Miner Res 31:1429\u20131439. doi:\n                        10.1002\/jbmr.2804","journal-title":"J Bone Miner Res"},{"key":"1719_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0662-6","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Dempster DW (2017) Histomorphometric changes following treatment for osteoporosis. J Endocrinol Invest. doi:\n                        10.1007\/s40618-017-0662-6","journal-title":"J Endocrinol Invest"},{"key":"1719_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/jbmr.362","volume":"26","author":"KE Hansen","year":"2011","unstructured":"Hansen KE, Wilson HA, Zapalowski C et al (2011) Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 26:1989\u20131996. doi:\n                        10.1002\/jbmr.362","journal-title":"J Bone Miner Res"},{"key":"1719_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s12020-016-1146-8","volume":"54","author":"G Mazziotti","year":"2016","unstructured":"Mazziotti G, Formenti AM, Adler RA et al (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH\/IGF-I and PTH\/VITAMIN D axes, treatment options and guidelines. Endocrine 54:603\u2013611. doi:\n                        10.1007\/s12020-016-1146-8","journal-title":"Endocrine"},{"key":"1719_CR21","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00198-013-2379-5","volume":"24","author":"P Farahmand","year":"2013","unstructured":"Farahmand P, Marin F, Hawkins F et al (2013) Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int 24:2971\u20132981. doi:\n                        10.1007\/s00198-013-2379-5","journal-title":"Osteoporos Int"},{"key":"1719_CR22","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Eng J Med 357:2028\u20132039. doi:\n                        10.1056\/NEJMoa071408","journal-title":"N Eng J Med"},{"key":"1719_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coph.2016.02.012","volume":"28","author":"T Harsl\u01fff","year":"2016","unstructured":"Harsl\u01fff T, Langdhal BL (2016) New horizons in osteoporosis therapies. Curr Opin Pharmacol 28:38\u201342","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"1719_CR24","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"SE Papapoulos","year":"2015","unstructured":"Papapoulos SE, Lippuner K, Roux C et al (2015) The effect of 8 or 5\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteopros Int 26(12):2773\u20132783. doi:\n                        10.1007\/s00198-015-3234-7","journal-title":"Osteopros Int"},{"issue":"9","key":"1719_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ncpendmet0941","volume":"4","author":"SE Papapoulos","year":"2008","unstructured":"Papapoulos SE, Makras P (2008) Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract End Metab 4(9):514\u2013523. doi:\n                        10.1038\/ncpendmet0941","journal-title":"Nat Clin Pract End Metab"},{"issue":"7","key":"1719_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40618-016-0437-5","volume":"39","author":"RA Adler","year":"2016","unstructured":"Adler RA (2016) Osteoporosis treatment: complexities and challenges. J Endocrinol Invest 39(7):719\u2013720. doi:\n                        10.1007\/s40618-016-0437-5","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"1719_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733. doi:\n                        10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"1719_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Od\u00e9n A et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175. doi:\n                        10.1007\/s00198-003-1514-0","journal-title":"Osteoporos Int"},{"key":"1719_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY et al (2017) Effects of Abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32:17\u201323. doi:\n                        10.1002\/jbmr.2991","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1719_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/14712598.2014.895808","volume":"14","author":"AG Costa","year":"2014","unstructured":"Costa AG, Bilezikian JP, Lewiecki EM (2014) Update on romosozumab: a humanized monoclonal antibody to sclerostin. Expert Opin Biol Ther 14(5):697\u2013707. doi:\n                        10.1517\/14712598.2014.895808","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"1719_CR31","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1210\/jc.2010-0720","volume":"95","author":"MT Drake","year":"2010","unstructured":"Drake MT, Srinivasan B, M\u00f6dder UI et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056\u20135062. doi:\n                        10.1210\/jc.2010-0720","journal-title":"J Clin Endocrinol Metab"},{"key":"1719_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3275\/8522","volume":"35","author":"S Piemonte","year":"2012","unstructured":"Piemonte S, Romagnoli E, Bratengeier C et al (2012) Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest 35:866\u2013868. doi:\n                        10.3275\/8522","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1719_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747\u2013783. doi:\n                        10.1210\/er.2011-1060","journal-title":"Endocr Rev"},{"issue":"16","key":"1719_CR34","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Eng J Med 375(16):1532\u20131543","journal-title":"N Eng J Med"},{"key":"1719_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA et al (2017) Effects of Romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:181\u2013187. doi:\n                        10.1002\/jbmr.2932","journal-title":"J Bone Miner Res"},{"key":"1719_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29:935\u2013943. doi:\n                        10.1002\/jbmr.2092","journal-title":"J Bone Miner Res"},{"key":"1719_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.2489","volume":"30","author":"CP Recknor","year":"2015","unstructured":"Recknor CP, Recker RR, Benson CT (2015) The effect of discontinuing treatment with Blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J Bone Miner Res 30:1717\u20131725. doi:\n                        10.1002\/jbmr.2489","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1719_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","volume":"26","author":"HG Bone","year":"2015","unstructured":"Bone HG, Dempster DW, Eisman JA et al (2015) Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the long-term odanacatib fracture trial. Osteoporos Int 26(2):699\u2013712. doi:\n                        10.1007\/s00198-014-2944-6","journal-title":"Osteoporos Int"},{"key":"1719_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00198-014-2971-3","volume":"26","author":"MM Bonafede","year":"2015","unstructured":"Bonafede MM, Shi N, Bower AG et al (2015) Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos Int 26:1203\u20131212. doi:\n                        10.1007\/s00198-014-2971-3","journal-title":"Osteoporos Int"},{"key":"1719_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198\u2013202. doi:\n                        10.1002\/jbmr.3051","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1719_CR41","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C et al (2009) Effects of Teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94(10):3772\u20133780. doi:\n                        10.1210\/jc.2008-2719","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1719_CR42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to 2\u00a0years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3):852\u2013860. doi:\n                        10.1210\/jc.2007-0711","journal-title":"J Clin Endocrinol Metab"},{"key":"1719_CR43","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/jbmr.1853","volume":"28","author":"F Cosman","year":"2013","unstructured":"Cosman F, Keaveny TM, Kopperdahl D et al (2013) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 28:1328\u20131336. doi:\n                        10.1002\/jbmr.1853","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1719_CR44","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694\u20131700. doi:\n                        10.1210\/jc.2013-4440","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"1719_CR45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155. doi:\n                        10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"1719_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide follow-up study (DATA-follow-up). Bone 98:54\u201358. doi:\n                        10.1016\/j.bone.2017.03.006","journal-title":"Bone"},{"issue":"5","key":"1719_CR47","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27(5):1923\u20131925. doi:\n                        10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-017-1719-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-017-1719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T08:08:07Z","timestamp":1506326887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-017-1719-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1719"],"URL":"https:\/\/doi.org\/10.1007\/s11739-017-1719-4","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,5]]}}}